Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Limited, a biotech firm specializing in cell therapy for cancer treatment, has issued 500,000 ordinary shares under the exemptions of the Corporations Act without the need for a disclosure document. Their lead product, ALA-101, targets blood cancers using CAR19-iNKT cells and they’re expanding into solid tumor treatments with new licensing and technology. The company complies with all necessary provisions and has no undisclosed ‘excluded information’ as of the release date.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
